SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia

drug to be administered

TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.